KRAS and pancreatic neoplasm: reported that MMRi62, a small molecule targeting the MDM2‐MDM4 axis, was able to induce degradation of FTH1 and mutant p53 to inhibit proliferation, clonogenic, and spheroid growth in pancreatic cancer cell lines harbouring either KRAS and TP53 double mutations or single TP53 mutation by inducing ferroptosis.23